Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013;Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d'intérêt en Hémostase Périopératoire (GIHP) - mars 2013

Annales Francaises d'Anesthesie et de Reanimation

Volumn 32, Issue 10, 2013, Pages 691-700

  Pernod, G ^a,b   Albaladejo, P ^a,b   Godier, A ^c   Samama, C M ^c   Susen, S ^d   Gruel, Y ^e   Blais, N ^f   Fontana, P ^g   Cohen, A ^h   Llau, J V ⁱ   Rosencher, N ^j   Schved, J F ^k   de Maistre, E ^l   Samama, M M ^c   Mismetti, P ^m   Sie P ⁿ  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b LABORATOIRE TIMC IMAG   (France)

^c HÔTEL DIEU   (France)

^d Centre de Biologie Pathologie   (France)

^e Laboratoire d'hémostase   (France)

^f NOTRE DAME HOSPITAL   (Canada)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j Institut Cochin   (France)

^k HÔPITAL SAINT ELOI   (France)

^l HÔPITAL DU BOCAGE   (France)

^m HÔPITAL NORD   (France)

ⁿ CHU RANGUEIL   (France)

more..

Author keywords

Anti IIa; Anti Xa; Emergency; Haemorrhage; Oral anticoagulant; Reversal; Surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; DABIGATRAN; PROTHROMBIN COMPLEX; RIVAROXABAN;

ANTICOAGULATION; ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; EMERGENCY SURGERY; HEMOSTASIS; HUMAN; LONG TERM CARE; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN TIME; SURGICAL RISK;

ANTI-IIA; ANTI-XA; ANTICOAGULANTS ORAUX; CHIRURGIE; EMERGENCY; HAEMORRHAGE; HÉMORRAGIE; ORAL ANTICOAGULANT; REVERSAL; RÉVERSION; SURGERY; URGENCE;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; EMERGENCIES; EMERGENCY MEDICAL SERVICES; FACTOR XA; HEMORRHAGE; HEMOSTASIS; HUMANS; MORPHOLINES; PERIOPERATIVE CARE; SURGICAL PROCEDURES, OPERATIVE; THIOPHENES; THROMBIN;

EID: 84886591493     PISSN: 07507658     EISSN: 17696623     Source Type: Journal    
DOI: 10.1016/j.annfar.2013.04.016     Document Type: Article

References (27)

1. Sié P., Samama C.M., Godier A., Rosencher N., Steib A., Llau J.V., et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis. Arch Cardiovasc Dis 2011, 104:669-676.
2. Healey J.S., Eikelboom J., Douketis J., Wallentin L., Oldgren J., Yang S., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012, 126:343-348.
3. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
4. EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
5. The EINSTEIN-PE Investigators, Büller H.R., Prins M.H., Lensin A.W., Decousus H., Jacobson B.F., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
6. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
7. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
8. Lu G., DeGuzman F.R., Hollenbach S.J., Karbarz M.J., Abe K., Lee G., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, [doi:10.1038/nm.3102].
9. Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
10. Marlu R., Paris A., Hodaj E., Albaladejo P., Polack B., Pernod G. Reversal of anticoagulant effect of Dabigatran and Rivaroxaban by non-specific reversal agents: a randomized crossover ex-vivo study in healthy volunteers. Thromb Haemost 2012, 108:217-224.
11. Dentali F., Marchesi C., Pierfranceschi M.G., Crowther M., Garcia D., Hylek E., et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011, 106:429-438.
12. Key N.S., Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007, 370:439-448.
13. Dager W., Roberts A. Reversing dabigatran with FEIBA in a patient with a transeptal perforation during cardiac ablation. Crit Care Med 2011, 39:867.
14. Godier A., Miclot A., Le Bonniec B., Durand M., Fischer A.M., Emmerich J., et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse Rivaroxaban in a rabbit model. Anesthesiology 2012, 116:1-9.
15. Zhou W., Schwarting S., Illanes S., Liesz A., Middelhoff M., Zorn M., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor Dabigatran. Stroke 2011, 42:3594-3599.
16. Samama M.M., Contant G., Spiro T.E., Perzborn E., Guinet C., Gourmelin Y., et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012, 107:379-387.
17. Weitz J.I., Quinlan D.J., Eikelboom J.W. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation 2012, 126:2428-2432.
18. Douxfils J., Mullier F., Robert S., Chatelain C., Chatelain B., Dogné J.M. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012, 107:985-997.
19. Perzborn E., Straussburger J., Pohlmann J., Roehrig S., Schlemmer K.H., Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct factor Xa inhibitor. J Thromb Haemost 2005, 3:514-521.
20. Samama M.M., Martinoli J.L., LeFlem L., Guinet C., Plu-Bureau G., Depasse F., et al. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010, 103:815-825.
21. Douxfils J., Mullier F., Loosen C., Chatelain C., Chatelain B., Dogné J.M. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012, 130:956-966.
22. Hillarp A., Baghaei F., Fagerberg Blixter I., Gustafsson K.M., Stigendal L., Sten-Linder M., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011, 9:133-139.
23. Dansirikul C., Lehr T., Liesenfeld K.H., Haertter S., Staab A. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost 2012, 107:775-785.
24. Clemens A., van Ryn J., Sennewald R., Yamamura N., Stangier J., Feuring M., et al. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. Eur J Clin Pharmacol 2012, 68:607-616.
25. Stangier J., Rathgen K., Stähle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268.
26. Mueck W., Lensing A.W., Agnelli G., Decousus H., Prandoni P., Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011, 50:675-686.
27. Pernod G., Godier A., Gozalo C., Tremey B., Sié P. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010, 126:167-174. French National Authority for Health.